阿托他汀钙、阿司匹林联用对原发性高血压血栓前状态的临床干预  

The Clinical Intervention of Lipitor-aspirin Combination in Prothrombotic State in Essential Hypertension (EH)

作　　者：劳永光[1] 刘华荣[1] 黎以斌[1] 钱耀华[1] 

机构地区：[1]广东医学院附属湛江中心医院心内三科,湛江524037

出　　处：《中国临床医学》2005年第1期19-20,共2页Chinese Journal of Clinical Medicine

摘　　要：目的:观察阿托他汀钙、阿司匹林联用对原发性高血压血栓前状态的临床干预。方法:60例原发性高血压血栓前状态分子标志物异常患者,在基础降压下随机分成2组,治疗组用立普妥10mg和阿司匹林0.1g,每日1次,口服。对照组用阿司匹林0.1g,每日1次,口服。治疗4周后监测全部患者的血栓前状态分子标志物的变化,并对两组患者进行疗效对比。结果: 治疗组患者治疗后的血栓前状态分子标志物的水平有极显著下降(P<0.01),对照组患者治疗后的血栓前状态分子标志物的水平有显著下降(P<0.05),但治疗组间治疗前后变化值与对照组间治疗前后的变化值更有显著下降(P<0.01)。结论:阿托他汀钙、阿司匹林联用对原发性高血压血栓前状态患者的干预有显著疗效(P<0.01)。Objective:To observe the clinical intervention of lipitor-aspirin combination in prothrombotic state in EH. Methods: Sixty patients with abnormal molecular markers in prothrombotic state in EH were randomly divided into two groups,under the condition of lowering blood pressure basically. The treated group was given lipitor 10 mg and aspirin 0. 1g once daily, while controls were given aspirin 0.1g once daily. The changes of molecular markers in all patients had been monitored after treatment for 4 weeks. The effects of therapy in two groups were compared. Results: The changes of molecular markers before and after treatment in the treated group were significantly decreased(P<0. 01) ,and that in the control group were significantly decreased too (P<0. 05). The decrease of the levels of markers in the treated group was much more than that of in the control group(p< 0. 01). Conclusion:The intervention of lipitor-aspirin combination on prothrombotic state in EH has obtained obvious effect(p<0. 01).

关 键 词：血栓前状态 阿司匹林 患者 原发性高血压 他汀 分子标志物 临床干预 下降 立普妥 目的 

分 类 号：R541[医药卫生—心血管疾病] R544.1[医药卫生—内科学]